Arrowhead Research | ARWR - Gross Profit On Sales


Arrowhead Research reported $73.74M in Gross Profit on Sales for its fiscal quarter ending in March of 2026.





Gross Profit On Sales Change Date
Agios Pharmaceuticals USD 19.43M 1.34M Mar/2026
Alnylam Pharmaceuticals USD 992.69M 167.68M Jun/2026
Anika Therapeutics USD 19.18M 3.6M Dec/2025
Arrowhead Research USD 73.74M 190.3M Mar/2026
Heron Therapeutics USD 29.47M 3.17M Dec/2025
Incyte USD 1.57B 400.89M Jun/2026
Ionis Pharmaceuticals USD 265M 22M Jun/2026
Ligand Pharmaceuticals USD 100.41M 51.96M Jun/2026
Merck USD 12.09B 1.24B Mar/2026
Moderna USD -566M 792M Mar/2026
Nektar Therapeutics USD 10.86M 10.95M Mar/2026
Novartis USD 11.24B 1.18B Jun/2026
Sarepta Therapeutics USD 251.15M 370.2M Jun/2026
TG Therapeutics USD 199.14M 27.73M Jun/2026
Ultragenyx Pharmaceutical USD 180M 74M Jun/2026
Vertex Pharmaceuticals USD 2.84B 242.4M Jun/2026
Xencor USD 51.22M 46.7M Jun/2026